Affordable Access

deepdyve-link
Publisher Website

Current treatment options for primary immune thrombocytopenia.

Authors
  • Salama, Abdulgabar
Type
Published Article
Journal
Expert Review of Hematology
Publisher
Informa UK (Taylor & Francis)
Publication Date
Feb 01, 2011
Volume
4
Issue
1
Pages
107–118
Identifiers
DOI: 10.1586/ehm.10.76
PMID: 21322783
Source
Medline
License
Unknown

Abstract

Traditional treatment of primary (idiopathic) immune thrombocytopenia (ITP) predominantly consists of immune suppression and/or modulation. In addition, many treated patients develop severe adverse effects, and approximately a third of patients do not respond. Two of the newly developed thrombopoietin-receptor agonists, romiplostim and eltrombopag, are now available for the treatment of ITP. Both drugs have been shown to increase the production of platelets in a dose-dependent manner, and to compensate, at least partly, for thrombocytopenia in the majority of ITP patients. The reported adverse effects are predominantly mild, although serious and long-term side effects cannot be excluded. Nevertheless, these drugs are increasingly used in the treatment of patients with thrombocytopenias. Thrombopoietin-receptor agonists do not appear to stop either the production of autoantibodies or the accelerated platelet destruction observed in ITP. Thus, the need for a specific therapy is essential, and the ultimate solution is to clarify and halt the mechanism(s) that lead to the development of ITP.

Report this publication

Statistics

Seen <100 times